Q1 report Thursday, 27 April, 07:00 CET '23e EBIT -2%, '24e EBIT up 1% 26-7x EBIT '23e-'24e, 18% org...
We make only minor estimate revisions following the Q1 report, which was in line with the preliminar...
Redeye comments on Cantargia’s completed enrolment of NSCLC patients in CANFOUR on April 21.
Finnair reports Q1 results on Apr 27. Finnair has lagged its peers in terms of pandemic recovery due...
Partnern Pointmedia signerar avtal med Mycoteam I december ingick XMReality och Pointmedia ett partn...
Q1 results show market share gains and operation improvement '23e-'25e EBITDA up 1% Trading at 34x '...
Plejd rapporterade första kvartalet för 2023 och nettoomsättningen uppgick till 121,3 MSEK, en öknin...
Redeye updates its estimates and valuation following Vitec releasing its Q1 2023 report.
Redeye thinks the likely termination of the EUR24m 5G contract, with almost half of the delivery lef...
Q1e: EBIT of SEK 90mChinese NBSK import price down ~20% YTDFair value range: SEK 10-15/sh (11-16)Q1e...
Q1 NOI in line, IFPM -5% on higher financial costsRevised 2025 IFPM target (SEK 1.
Q1 came in better than expected on sales and ordersWe lower '23e-'25e EBIT by 12-6% on higher opex0.
Redeye comments on Cereno Scientific’s rights issue that was announced yesterday.
Over the past week, several noteworthy events have occurred while Scandinavian Chemotech’s TO3 moves...
Q1'23 results Nexam had Q1 sales of SEK 52m (ABGSCe SEK 59m), whereof sales to Diab were SEK ~10m.
We maintain our estimates intact ahead of Atria’s Q1 due on 25 April.
Ny intäktsmix sedan storförvärv… I samband med att Albert tillträde förvärven av bolagen Film och Sk...
Bra resultat givet förutsättningarna BE Group rapporterade en underliggande EBIT på 10 mkr (180 mkr ...
Redeye comments on the news that Mestro has been accepted into the SKYLINE accelerator program, a co...
Vitrolife’s enters 2023 with good progress. The organic growth is 9%, with support from all three li...
